Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

44.74 -1.11 (-2.42%)
Streaming Delayed Price Updated: 9:35 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
News headline image
7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
News headline image
6 Analysts Have This To Say About Corcept Therapeutics ↗
 
Via Benzinga
News headline image
NASDAQ:CORT is not too expensive for the growth it is showing. ↗
NASDAQ:CORT is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? ↗
Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Phase 4 CATALYST Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter ↗
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... 
Via Benzinga
News headline image
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.